Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,816.89
(
-0.11%
)
US TECH 100
24,486.40
(
0.32%
)
Dow Jones
47,916.57
(
-0.56%
)
Brent Oil
92.41
(
0.00%
)
Bitcoin
73,042.15
(
0.09%
)
News Focus
News Focus
Post# of 257382
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122860
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 247127

Tuesday, 12/12/2023 10:53:17 AM

Tuesday, December 12, 2023 10:53:17 AM

Post# of 257382
AZN acquires ICVX for $15/sh cash +CVR—a 43% premium to yesterday’s close (excluding the CVR):

https://www.businesswire.com/news/home/20231212478740/en

ICVX’s lead program is a combination vaccine for RSV and hMPV that AZN says is ready to go into phase-3 trials. The nominal deal value (excluding the CVR) is $800M.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today